LFCR - Multiplikator Forward P/S Lifecore Biomedical, Inc.

Lifecore Biomedical (LFCR) cash flows depend on the reliability of external raw material suppliers. The forward P/S dynamics of the company confirm these links, where 1.30 reflects the baseline level of the metric. Internal optimization has ensured working capital stability, while unique expertise in syringe filling has solidified its status as an indispensable partner in the production of innovative injectables for the market's largest players.

Lifecore Biomedical, Inc. - Rega mangsa ngarep marang pendapatan LFCR (periode 28.04.2023 - 31.08.2026)

Ringkesan rincian data analitis lifecore.com (LFCR)

- rega pasar lan target rega analis:

Bagan rega Lifecore Biomedical, Inc.|LFCR - Bagan rega target

- statistik kapitalisasi pasar:

Kapitalisasi pasar Lifecore Biomedical, Inc.|LFCR - Rega Tumbas Perusahaan

- statistik nilai buku emiten:

Nilai Buku saben Saham Lifecore Biomedical|LFCR - Nilai Aset Bersih|Rasio Kapitalisasi Pasar marang Nilai Buku lifecore.com|LFCR - Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Total Utang marang Modal Lifecore Biomedical|LFCR - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Lifecore Biomedical, Inc.|LFCR - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Lifecore Biomedical, Inc.|LFCR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Lifecore Biomedical|Indikator likuiditas cepet lifecore.com

- rincian asil keuangan lan kelipatan valuasi:

LFCR - Bathi pungkasan|Proyeksi bathi mangsa ngarep Lifecore Biomedical|LFCR - Rasio rega marang bathi|Pangali Forward P/E Lifecore Biomedical, Inc.|LFCR - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Lifecore Biomedical, Inc.|LFCR - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Lifecore Biomedical|LFCR - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan lifecore.com|LFCR - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Lifecore Biomedical

- informasi babagan volume dodolan lan pendapatan:

LFCR - Volume dodolan perusahaan|Prakiraan volume dodolan Lifecore Biomedical, Inc.|LFCR - Koefisien rega marang pendapatan|Multiplikator Forward P/S Lifecore Biomedical, Inc.

Analisis wiwitan perusahaan:LFCR (Lifecore)

Lifecore Biomedical (LFCR) is optimizing contract manufacturing transparency to restore market confidence, making the monitoring of revenue generation efficiency critical. The current value of 1.30 reflects the ratio of market capitalization to projected sales, allowing investors to use the forward price-to-sales ratio to assess the risk of asset undervaluation and the business's ability to sustain demand amid macroeconomic volatility.

Pesaing wigati

Rasio rega marang prakiraan pendapatan IQVIA IQV|Labcorp Holdings - Rasio rega marang prakiraan pendapatan|Medpace Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake ICON Public ICLR|CRL: Multiplikator Forward P/S|Rega mangsa ngarep marang pendapatan EVO (evotec.com)|FTRE (Fortrea) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OmniAb Inc. OABI|Multiplikator Forward P/S NOTV|Multiplikator forward rega marang pendapatan Avid Bioservices Inc CDMO|Rasio rega marang prakiraan pendapatan Catalent, Inc. CTLT|nighthawkbio.com (SCPX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep